Replies to post #247677 on Avid Bioservices Inc (CDMO)

[cjgaddy]

PPHM's Jeff Hutchins(VP/PreClinRes) speaking 3-8-16 at CHI’s Inaugural-Cancer-Immunotherapy Conf. (SanFran). Dr. Hutchins is chairing the “Emerging Strategies For Checkpoint Inhibitor Combination Immunotherapy” track…

Mar6-11 2016: “CHI’s 23rd Molecular Med. TRI-CON 2016”, SanFran http://www.triconference.com
"Attracting over 3,300 drug discovery & dev. professionals from over 40 countries in 2015, the Tri-Conference has grown into a diverse event, focusing on Molecular Medicine, specifically on Discovery, Genomics, Diagnostics, and Info. Technology."
CHI = Cambridge Healthtech Institute http://www.healthtech.com
INAUGURAL CANCER IMMUNOTHERAPY CONF. - Emerging Biology, Targets and Strategies
Mar7–9 2016 (part of the 23rd Intl. Molecular Medicine Tri-Conf.)
http://www.triconference.com/Cancer-Immunotherapy
Track: EMERGING STRATEGIES FOR CHECKPOINT INHIBITOR COMBINATION IMMUNOTHERAPY
Chairperson: Jeff T. Hutchins (PhD, VP/PreclinRes., Peregrine Pharm.)
3-8-16 2pm: Chairperson Jeff Hutchins' Remarks
3-8-16 3:55pm: “Combination Immunotherapies – Opening the Gate: Increasing Tumor Infiltrating Activated T-Cells to Optimize and Expand the Benefits of Immune Checkpoint Therapies” Jeff T. Hutchins (Peregrine)
OVERVIEW: PD-1 & CTLA-4-targeting drugs have significantly improved patient survival in both melanoma and NSCLC, although their efficacy has been limited to a minority of subjects. Phosphatidylserine (PS)-targeting antibodies have demonstrated the ability to override tumor immune suppression and reactivate immune responses when combined with immunotherapies, chemotherapies, radiation, and targeted treatments. Recent translational data demonstrate the potential of PS-targeting antibodies to mediate immune activation and improved anti-tumor responses in low PD-L1 tumor samples.

[hutschi]

Energy disruptors: rising stars in anticancer therapy?

The metabolic features of tumor cells diverge from those of normal cells. Otto Warburg was the first to observe that cancer cells dramatically increase their glucose consumption to generate ATP. He also claimed that cancer cells do not have functional mitochondria or oxidative phosphorylation (OXPHOS) but simply rely on glycolysis to provide ATP to the cell, even in the presence of oxygen (aerobic glycolysis). Several studies have revisited this observation and demonstrated that most cancer cells contain metabolically efficient mitochondria. Indeed, to sustain high proliferation rates, cancer cells require functional mitochondria to provide ATP and intermediate metabolites, such as citrate and cofactors, for anabolic reactions. This difference in metabolism between normal and tumors cells causes the latter to be more sensitive to agents that can disrupt energy homeostasis. In this review, we focus on energy disruptors, such as biguanides, 2-deoxyglucose and 5-aminoimidazole-4-carboxamide ribonucleotide, that interfere with the main metabolic pathways of the cells, OXPHOS, glycolysis and glutamine metabolism. We discuss the preclinical data and the mechanisms of action of these disruptors at the cellular and molecular levels. Finally, we consider whether these drugs can reasonably contribute to the antitumoral therapeutic arsenal in the future.

http://www.nature.com/oncsis/journal/v5/n1/full/oncsis201546a.html

[biopharm]

Jan25-27 2016: “Phacilitate's Immunotherapy World Conf.”, WashDC
www.immunotherapyforum.com/Content/Conference
“After years of posting impressive clinical results and pushing analyst projections to greater and greater heights, immuno-oncology has solidified its status as the most exciting development in cancer treatment for a long time. Now that checkpoint inhibitors have uncloaked cancer cells, drug developers are investigating dozens of immune drug cocktails (everything from CAR-T to antibodies, vaccines and other cellular therapies) to find well-tolerated treatments which could become the first-in-line to fight cancer in patients. We have all heard of the stunning breakthroughs at ASCO'15. BMS’ Opdivo + Yervoy study which lead to a 58% shrinkage of tumors and a PFS superiority of 8.6mos. against monotherapies in patients with melanoma. AstraZeneca’s own PD-L1 (MEDI4736/durvalumab) [see 10-15-15 AZN/PPHM Collab. Expansion: http://tinyurl.com/q79bkam ] and CTLA-4 (Tremelimumab) inhibitor combination, which demonstrated an ORR of 27% in the treatment of NSCLC… On Jan25-27 2016, 750 deal-makers will gather in the Grand Hyatt Hotel to discuss the direction, future and value of cell, gene and immunotherapy portfolios.”
---------
Jan25(Day1): Focus Session1, “Cellular Cancer Immunotherapy: Optimizing Combination Therapy Development Strategy”
2:40-2:55pm: Chair's intro, David Lebwohl, NOVARTIS
2:55-3:10pm: Michael Hanna, VACCINOGEN, “The Provocative Issues of Tumor Heterogeneity on Active Specific Immunotherapy...”
3:10-3:25pm: Laura Benjamin, ELI LILLY, “Challenges/Opportunities for Translational Science to Guide Angiogenesis/Combos w/Immunotherapy”
3:25-3:40pm: Taylor Schreiber, HEAT BIOLOGICS, “Dual-Acting Immunotherapy with ComPACT - Vaccination & Co-Stimulation...”

------------------

CJ, Laura Benjamin... I get a sense Eli Lilly will pop up in Peregrines future...

Next, we have "Laura E. Benjamin" from Eli Lilly and her profile goes from Harvard to Eli Lilly with no other stops working with no other Big Pharmas and unique in that she only places 8 companies on her profile (at the time I discovered it months back) though now she has 12 companies on there. Well... originally Peregrine Pharmaceuticals was listed on the original 8 and why?

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113758479